Veru Posts Mixed Q4 Results

  • Veru Inc VERU reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million.
  • FC2 prescription net revenues climbed 55% Y/Y to $13.6 million.
  • Gross profit rose 29% to $12.3 million, while the margin contracted 200 basis points Y/Y to 79%.
  • The operating loss for the quarter narrowed to $(1.9) million.
  • The company held $122.4 million in cash and equivalents as of September 30, 2021.
  • EPS loss of $(0.05) beat the analyst consensus of $(0.09).
  • Price Action: VERU shares traded lower by 2.32% at $6.75 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsSmall CapMoversTrading IdeasBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!